02 July 2026
: Case report 
Tacrolimus-Induced Thrombotic Microangiopathy in a Kidney Transplant Recipient After Treatment for Acute Allograft Rejection
Unusual clinical course, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Diagnostic / therapeutic accidents, Adverse events of drug therapy, Clinical situation which can not be reproduced for ethical reasons
Yen-Hao Liao ABDEF 1*, Ming-Yi Huang DF 1DOI: 10.12659/AJCR.953247
Am J Case Rep 2026; 27:e953247
Figure 1 Diagnostic algorithm for suspected drug-induced thrombotic microangiopathy, including confirmation of microangiopathic hemolytic anemia and stepwise exclusion of secondary causes before implicating tacrolimus. Abbreviations: ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; APLA, antiphospholipid antibodies; BKV, BK virus; CMV, cytomegalovirus; COVID-19, coronavirus disease 2019; dsDNA, double-stranded DNA; GBM, glomerular basement membrane; RF, rheumatoid factor; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura.